TREA

11-Deoxy-trans-4,5-didehydro-PGI.sub.1 compounds

Follow

Information

  • Patent Grant
  • 4202970
  • Patent Number
    4,202,970
  • Date Filed
    Thursday, August 31, 1978
    46 years ago
  • Date Issued
    Tuesday, May 13, 1980
    44 years ago
Information
Abstract
The present invention relates to certain structural and pharmacological analogs of prostacyclin (PGI.sub.2) which are 11-deoxy-trans-4,5-didehydro-PGI.sub.1 compounds. These novel pharmacological agents are useful as smooth muscle stimulators.
Description

The present invention provides novel pharmacological agents, the preparation and use of which is described in U.S. Pat. No. 4,109,182, issued Aug. 22, 1978, the relevant portion of which is incorporated here by reference. These pharmacological agents are characterized by smooth muscle stimulatory actions and are related structurally to prostacyclin, being 11-deoxy-trans-4,5-didehydro-PGI.sub.1 compounds.
Claims
  • 1. A prostacyclin analog of the formula ##STR1## wherein Y.sub.1 is trans--CH.dbd.CH--, cis--CH.dbd.CH--, or --CH.sub.2 CH.sub.2 --;
  • wherein Z.sub.2 is ##STR2## wherein Z.sub.1 is (1) --(CH.sub.2).sub.g --CH.sub.2 --CH.sub.2 --, or
  • (2) --(CH.sub.2).sub.g --CH.sub.2 --CF.sub.2 --,
  • wherein g is the integer zero, one, or 2;
  • wherein R.sub.8 is hydrogen or hydroxymethyl;
  • wherein M.sub.1 is ##STR3## wherein R.sub.5 is hydrogen or alkyl with one to 4 carbon atoms, inclusive,
  • wherein L.sub.1 is ##STR4## or a mixture of ##STR5## wherein R.sub.3 and R.sub.4 are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R.sub.3 and R.sub.4 is fluoro only when the other is hydrogen or fluoro;
  • wherein R.sub.1 is hydrogen; alkyl of one to 12 carbon atoms, inclusive; cycloalkyl of 3 to 10 carbon atoms, inclusive; aralkyl of 7 to 12 carbon atoms, inclusive; phenyl; phenyl substituted with one, two or three chloro or alkyl of one to 3 carbon atoms; phenyl substituted in the para position by ##STR6## wherein R.sub.25 is methyl, phenyl, acetamidophenyl, benzamidophenyl, or --NH.sub.2 ; R.sub.26 is methyl, phenyl, --NH.sub.2, or methoxy; and R.sub.27 is hydrogen or acetamido, inclusive; phenacyl, i.e., ##STR7## phenacyl substituted in the para position by chloro, bromo, phenyl, or benzamido; or a pharmacologically acceptable cation;
  • wherein R.sub.7 is ##STR8## wherein m is the integer one to 5, inclusive, h is the integer zero to 3, inclusive; s is the integer zero, one, 2, or 3, and T is chloro, fluoro, trifluoromethyl, alkyl of one to 3 carbon atoms, inclusive, or alkoxy of one to 3 carbon atoms, inclusive, with the proviso that not more than two T's are other than alkyl.
  • 2. A prostacyclin analog according to claim 1, wherein Y.sub.1 is trans--CH.dbd.CH--.
  • 3. A prostacyclin analog according to claim 2, wherein R.sub.8 is hydroxymethyl.
  • 4. A prostacyclin analog according to claim 3, wherein Z.sub.2 is a mixture of ##STR9##
  • 5.
  • trans-4,5-Didehydro-(6RS)-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 4.
  • 6. A prostacyclin analog according to claim 3, wherein Z.sub.2 is ##STR10##
  • 7.
  • trans-4,5-Didehydro-6.alpha.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 6.
  • 8. 15-Methyl-trans-4,5-didehydro-6.alpha.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 6.
  • 9. 16,16-Dimethyl-trans-4,5-didehydro-6.alpha.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 6.
  • 10. 16,16-Difluoro-trans-4,5-didehydro-6.alpha.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 6.
  • 11. A prostacyclin analog according to claim 3, wherein Z.sub.2 is ##STR11##
  • 12. A prostacyclin analog according to claim 11, wherein Z.sub.1 is --(CH.sub.2).sub.g --CH.sub.2 --CF.sub.2 --.
  • 13. 2,2-Difluoro-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 12.
  • 14. A prostacyclin analog according to claim 11, wherein Z.sub.1 is --(CH.sub.2).sub.g --CH.sub.2 --CH.sub.2 --.
  • 15. A prostacyclin analog according to claim 14, wherein g is zero.
  • 16. A prostacyclin analog according to claim 15, wherein R.sub.7 is ##STR12##
  • 17. 17-Phenyl-18,19,20-trinor-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 16.
  • 18. A prostacyclin analog according to claim 15, wherein R.sub.7 is ##STR13##
  • 19. 16-Phenoxy-17,18,19,20-tetranor-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 18.
  • 20. A prostacyclin analog according to claim 15, wherein R.sub.7 is --(CH.sub.2).sub.m --CH.sub.3 --.
  • 21. A prostacyclin analog according to claim 20, wherein m is 3.
  • 22. A prostacyclin analog according to claim 21, wherein R.sub.5 is methyl.
  • 23. 15-Methyl-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 22.
  • 24. A prostacyclin analog according to claim 21, wherein R.sub.5 is hydrogen.
  • 25. A prostacyclin analog according to claim 24, wherein at least one of R.sub.3 and R.sub.4 is fluoro.
  • 26. 16,16-Difluoro-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 25.
  • 27. A prostacyclin analog according to claim 24, wherein at least one of R.sub.3 and R.sub.4 is methyl.
  • 28. 16,16-Dimethyl-trans-4,5-didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 27.
  • 29. A prostacyclin analog according to claim 24, wherein R.sub.3 and R.sub.4 are both hydrogen.
  • 30. trans-4,5-Didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, methyl ester, a prostacyclin analog according to claim 29.
  • 31. trans-4,5-Didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, tris(hydroxymethyl)amino methane salt, a prostacylin analog according to claim 29.
  • 32. trans-4,5-Didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, adamantanamine salt, a prostacyclin analog according to claim 29.
  • 33. trans-4,5-Didehydro-6.beta.-11-deoxy-11.alpha.-hydroxymethyl-PGI.sub.1, a prostacyclin analog according to claim 29.
  • 34. A prostacyclin analog according to claim 2, wherein R.sub.8 is hydrogen.
  • 35. A prostacyclin analog according to claim 34, wherein Z.sub.2 is a mixture of ##STR14##
  • 36. trans-4,5-Didehydro-(6RS)-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 35.
  • 37. A prostacyclin analog according to claim 34, wherein Z.sub.2 is ##STR15##
  • 38. trans-4,5-Didehydro-6.alpha.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 37.
  • 39. 15-Methyl-trans-4,5-didehydro-6.alpha.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 37.
  • 40. 16,16-Dimethyl-trans-4,5-didehydro-6.alpha.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 37.
  • 41. A prostacyclin analog according to claim 34, wherein Z.sub.2 is ##STR16##
  • 42. A prostacyclin analog according to claim 41, wherein Z.sub.1 is --(CH.sub.2).sub.g --CH.sub.2 --CF.sub.2 --.
  • 43. 2,2-Difluoro-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 42.
  • 44. A prostacyclin analog according to claim 41, wherein Z.sub.1 is --(CH.sub.2).sub.g --CH.sub.2 --CH.sub.2 --.
  • 45. A prostacyclin analog according to claim 44, wherein g is zero.
  • 46. A prostacyclin analog according to claim 45, wherein R.sub.7 is ##STR17##
  • 47. 17-Phenyl-18,19,20-trinor-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 46.
  • 48. A prostacyclin analog according to claim 45, wherein R.sub.7 is ##STR18##
  • 49. 16-Phenoxy-17,18,19,20-tetranor-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 48.
  • 50. A prostacyclin analog according to claim 45, wherein R.sub.7 is --(CH.sub.2).sub.m --CH.sub.3.
  • 51. A prostacyclin analog according to claim 50, wherein m is 3.
  • 52. A prostacyclin analog according to claim 51, wherein R.sub.5 is methyl.
  • 53. 15-Methyl-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 52.
  • 54. A prostacyclin analog according to claim 51, wherein R.sub.5 is hydrogen.
  • 55. A prostacyclin analog according to claim 54, wherein at least one of R.sub.3 and R.sub.4 is fluoro.
  • 56. 16,16-Difluoro-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 55.
  • 57. A prostacyclin analog according to claim 54, wherein at least one of R.sub.3 and R.sub.4 is methyl.
  • 58. 16,16-Dimethyl-trans-4,5-didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 57.
  • 59. A prostacyclin analog according to claim 54, wherein R.sub.3 and R.sub.4 are both hydrogen.
  • 60. trans-4,5-Didehydro-6.beta.-11-deoxy-PGI.sub.1, methyl ester, a prostacyclin analog according to claim 59.
  • 61. trans-4,5-Didehydro-6.beta.-11-deoxy-PGI.sub.1, tris(hydroxymethyl)amino methane salt, a prostacyclin analog according to claim 59.
  • 62. trans-4,5-Didehydro-6.beta.-11-deoxy-PGI.sub.1, adamantanamine salt, a prostacyclin analog according to claim 59.
  • 63. trans-4,5-Didehydro-6.beta.-11-deoxy-PGI.sub.1, a prostacyclin analog according to claim 59.
CROSS REFERENCE TO RELATED APPLICATION

The present application is a continuation-in-part of Ser. No. 821,542, filed Aug. 3, 1977, now pending.

Non-Patent Literature Citations (1)
Entry
Corey et al., J.A.C.S. 99:4/Mar. 1977, pp. 2006-2008.
Continuation in Parts (1)
Number Date Country
Parent 821542 Aug 1977